Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
Pharmaceutical companies, medical device makers, and drug wholesalers should be allowed to participate in Japan’s reimbursement policymaking on an equal footing with existing members of the Central Social Insurance Medical Council (Chuikyo), an Ishin lawmaker has told Jiho. Keishi Abe,…
To read the full story
Related Article
- JaDHA Calls for Digital Health Seat in Chuikyo Reform
September 28, 2026
- Digital Health Group Eager to Gain Full Seat at Chuikyo Table
September 25, 2026
- Health Minister Mum on Legislation for Chuikyo Reform
September 2, 2026
- A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
July 13, 2026
- LDP, Ishin Seal Social Security Deal, Set Course for Chuikyo Reform
July 8, 2026
- Opposition Party Member Calls for Chuikyo Reform
January 27, 2025
REGULATORY
- Japan Panel Again Defers Male HPV Shots amid Cost-Effectiveness Concerns
October 9, 2026
- Takaichi Defends Off-Year Drug Price Revisions as DPP Calls for Abolition
October 9, 2026
- Japan Orders Contraindication for Adlumiz-Noxafil Combination
October 9, 2026
- Imcivree, Hibsago Get Chuikyo Nod for Home Self-Injection
October 9, 2026
- Provider-Payer Tug-of-War Takes Shape over FY2027 Drug Price Revision
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…